Market Indices
Sector Heatmap
ELDN — Eledon Pharmaceuticals, Inc. Common Stock
NasdaqEledon Pharmaceuticals, Inc. Common Stock
- O
- 2.48
- H
- 2.55
- L
- 2.42
- V
- 960.37K
ELDN — Latest News & Headlines
7 StoriesNo reported rejections followed Eledon’s drug after six months, versus seven for tacrolimus. Phase 3 is expected in Q4 2026. - Stock Titan
No reported rejections followed Eledon’s drug after six months, versus seven for tacrolimus. Phase 3 is expected in Q4 2026. Stock Titan
Eledon Pharmaceuticals, Inc. (ELDN) Presents at International Congress of The Transplantation Society 2026 - Slideshow (NASDAQ:ELDN) 2026-09-22 - Seeking Alpha
Eledon Pharmaceuticals, Inc. (ELDN) Presents at International Congress of The Transplantation Society 2026 - Slideshow (NASDAQ:ELDN) 2026-09-22 Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN), Viking Therapeutics (VKTX) and Amgen (AMGN) - theglobeandmail.com
Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN), Viking Therapeutics (VKTX) and Amgen (AMGN) theglobeandmail.com
Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society - markets.businessinsider.com
Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society markets.businessinsider.com
Noble Financial Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Noble Financial Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $10 Moomoo
Eledon updates mid-stage trial data for lead drug (ELDN:NASDAQ) - Seeking Alpha
Eledon updates mid-stage trial data for lead drug (ELDN:NASDAQ) Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN), Lexeo Therapeutics, Inc. (LXEO) and Edgewise Therapeutics (EWTX) - theglobeandmail.com
Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN), Lexeo Therapeutics, Inc. (LXEO) and Edgewise Therapeutics (EWTX) theglobeandmail.com